Table 3 Prognostic factors for disease-free survival: multivariate analysis
|  | Model 1 (N = 570) |  | Model 2 (N = 575) |  |
|---|---|---|---|---|
| Â | HR (95 % CI) | p-valuea | HR (95 % CI) | p-valuea |
Age | ||||
  < 35 | 1 |  | 1 |  |
  ≥ 35 | 0.5 [0.1–2.3] | 0.581 | 0.5 [0.1–.396] | 0.440 |
SBR Grade | ||||
 1–2 | 1 |  | NA |  |
 3 | 2.8 [1.4–5.4] | 0.0027 | NA |  |
Pathological tumor size | ||||
 pT1 | 1 |  | 1 |  |
 pT2 | 0.9 [0.5–1.7] | 0.897 | 0.9 [0.5–1.7] | 0.916 |
 pT3-T4 | 0.4 [0.05–3.3] | 0.431 | 0.4 [0.06–3.4] | 0.447 |
PVI | ||||
 No | 1 |  | 1 |  |
 Yes | 1.5 [0.8–3.0] | 0.175 | 1.3 [0.7–2.6] | 0.357 |
Hormone receptors | ||||
 Negative | 1 |  | NA |  |
 Positive | 1.0 [0.5–2.2] | 0.818 | NA |  |
HER2 | ||||
 Positive | 1 |  | NA |  |
 Negative | 0.5 [0.2–1.4] | 0.239 | NA |  |
IHC subtypes | ||||
 Luminal A | NA |  | 1 |  |
 Luminal B/HER2-negative | NA |  | 4.2 [1.9–9.1] | 0.0002 |
 Luminal B/HER2-positive | NA |  | 0.7 [0.1–3.4] | 0.721 |
 HER2 | NA |  | 1.76 [0.4–6.1] | 0.38 |
 Triple-negative | NA |  | 2.5 [1.1–5.4] | 0.0201 |